Tumor neoantigen-presenting cells

“Tumor neoantigen-presenting cells” describes immune cells—primarily dendritic cells, macrophages, and B cells—that process and present tumor-specific neoantigens (novel peptides generated by somatic mutations in cancer cells) via MHC molecules to T lymphocytes. This antigen presentation is critical for the initiation and maintenance of tumor-specific T-cell-mediated immune responses, underlies the mechanism of many immunotherapies, and is a focus of vaccine and adoptive T-cell transfer strategies. Importantly, this is not a discrete molecule, protein, or receptor, but rather a descriptor of cell function and phenotype. Therefore, it is not an appropriate entry for a structured molecular target list. If a molecular target is required, please specify a protein/receptor involved in this neoantigen presentation process (e.g., “Major histocompatibility complex class I,” “Major histocompatibility complex class II,” or “CD40”).

Other names

Neoantigen-presenting cellsTumor-associated antigen-presenting cellsTumor-infiltrating antigen-presenting cellsAPCs presenting neoantigen

Presentation of tumor-derived neoantigens via MHC class I and II to activate CD8+ and CD4+ T cells